Prospective Study of NMR-based Serum Metabolic Profiles for the Diagnosis of Checkpoint Inhibitor-related Pneumonitis
Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of precise and effective diagnostic techniques often leads to underdiagnosis and misdiagnosis. The investigators conducted a prospective clinical study to evaluate the effectiveness of ¹H-nuclear magnetic resonance (NMR)-based lipoprotein and metabolite analysis in diagnosing checkpoint inhibitor-related pneumonitis (CIP), aiming to improve its early diagnosis rate.
• Patients with a pathological diagnosis of lung cancer;
• The subject has received at least one course of immune checkpoint inhibitor treatment;
• Capable of understanding and voluntarily signing an informed consent form.
• For the CIP group, the following additional criteria must be met:
• Highly suspected of having checkpoint inhibitor pneumonitis based on radiological abnormalities and/or pulmonary symptoms (including fever, cough, and dyspnea).
• For the Control group, the following additional criteria must be met:
• Has had no clinical symptoms or radiographic evidence suggestive of pneumonitis at enrollment or prior to enrollment.